News | September 29, 2025
AstraZeneca to harmonise its listing structure across LSE, STO and NYSE
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Completion of the demerger of Haleon and share consolidation of GSK
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Subscribe To Our Newsletter & Stay Updated
